influenza
viru
respiratori
syncyti
viru
rsv
detect
short
tat
pivot
rapid
decis
regard
treatment
infect
current
diagnost
detect
influenza
viru
rsv
includ
direct
antigen
detect
dad
viru
isol
cell
cultur
vic
nucleic
acid
amplif
test
nat
dad
rapid
shown
limit
sensit
compar
past
vic
gold
standard
sensit
specif
identif
respiratori
virus
carv
includ
influenza
virus
rsv
howev
vic
requir
skill
technician
dedic
cell
cultur
equip
tat
sever
day
limit
use
techniqu
special
contrast
nat
advantag
shorter
tat
approxim
hour
detect
multipl
pathogen
parallel
test
semiquantit
format
multiplexnat
recent
nat
platform
becam
avail
detect
influenza
virus
test
poct
besid
short
tat
less
hour
poct
simpl
oper
permit
use
set
without
extens
laboratori
train
howev
neg
result
difficult
interpret
sinc
poct
may
limit
sensit
ill
question
may
due
carv
cover
poct
reason
comparison
multiplexnat
assay
consider
fact
number
centr
explor
detect
coba
liat
influenza
ab
rsv
assay
liat
interest
sinc
influenza
well
target
caus
signific
morbid
younger
children
older
adult
cold
season
therefor
guid
initi
decis
regard
antivir
therapi
well
infect
control
first
phase
eight
extern
qualiti
assur
sampl
cover
influenza
rsv
test
liat
limit
detect
estim
use
twofold
serial
dilut
viru
transport
medium
vtm
patient
sampl
test
posit
either
influenza
rsv
quantit
nucleic
acid
amplif
qnat
prospect
parallel
studi
consecut
nasopharyng
swab
submit
routin
test
novemb
januari
swab
compar
use
liat
two
food
drug
administr
fda
multiplexnat
discord
result
liat
multiplexnat
resolv
qnat
briefli
nasopharyng
sampl
collect
use
copan
swab
adult
infant
submers
ml
vtm
liat
respiratori
specimen
transfer
dispos
assay
tube
use
steril
transfer
pipett
tube
cap
directli
insert
liat
analyz
xtag
respiratori
pathogen
panel
rpp
assay
use
http
wwwaccessdatafdagovscriptscdrhcfdocscfpmnpmncfm
luminex
molecular
diagnost
inc
netherland
total
nucleic
acid
extract
respiratori
specimen
use
viral
na
small
volum
kit
roch
diagnost
ag
rotkreuz
switzerland
accord
manufactur
instruct
nucleic
acid
collect
elut
buffer
use
accord
manufactur
instruct
cover
target
consist
adenoviru
coronaviru
human
bocaviru
human
metapneumoviru
human
rhinovirusenteroviru
parainfluenza
c
pneumonia
l
pneumophila
genmark
diagnost
carlsbad
ca
respiratori
sampl
mix
equal
volum
eplex
sampl
buffer
vortex
second
transfer
rpp
cartridg
follow
insert
eplex
system
cover
target
consist
adenoviru
coronaviru
human
bocaviru
human
metapneumoviru
human
rhinovirusenteroviru
middl
east
respiratori
syndrom
coronaviru
parainfluenza
b
pertussi
c
pneumonia
l
pneumophila
pneumonia
recent
receiv
ce
vitro
diagnostica
ivd
fda
qnat
influenza
virus
rsv
perform
previous
briefli
revers
transcript
influenza
identifi
amplifi
specif
sequenc
matrix
protein
wherea
specif
hemagglutinin
sequenc
target
identifi
influenza
detect
duplex
qnat
amplifi
specif
sequenc
nonstructur
protein
c
qnat
reaction
incub
minut
minut
follow
cycl
second
minut
reaction
mix
total
volum
ad
extract
nucleic
acid
revers
transcript
amplif
sampl
test
duplic
addit
replic
spike
copi
respect
plasmid
detect
amplif
inhibit
viral
load
patient
sampl
determin
qnat
quantif
plasmid
contain
correspond
region
pathogen
genom
use
triplic
copi
gener
standard
curv
extern
qualiti
assur
program
test
differ
type
differ
dilut
influenza
rsv
use
valid
statist
analys
perform
prism
softwar
version
graphpad
softwar
inc
la
jolla
ca
graphpad
softwar
graphpad
softwar
inc
la
jolla
ca
p
regard
statist
signific
eight
extern
qualiti
assur
sampl
correctli
identifi
influenza
n
influenza
n
n
n
concord
intend
qualiti
assur
result
liat
multiplexnat
result
directli
enter
laboratori
inform
system
electron
document
valid
detect
limit
liat
evalu
use
twofold
serial
dilut
patient
sampl
contain
influenza
rsv
influenza
liat
detect
dilut
correspond
copiesml
influenza
dilut
copiesml
rsv
dilut
contain
copiesml
prospect
studi
consist
respiratori
sampl
consecut
submit
routin
test
patient
present
ill
novemb
januari
figur
major
patient
year
younger
approxim
half
male
median
age
patient
year
percentil
month
th
percentil
year
rang
week
year
tabl
liat
sampl
posit
consist
influenza
influenza
rsv
case
one
hundr
fifti
sampl
analyz
remain
combin
multiplexnat
assay
identifi
influenza
influenza
rsv
posit
specimen
tabl
identifi
case
wherea
sampl
thu
concord
result
obtain
case
discord
result
four
sampl
consist
rsv
detect
three
case
confirm
qnat
copiesml
respect
fourth
discord
sampl
report
influenza
liat
neg
qnat
taken
togeth
liat
show
sensit
specif
influenza
influenza
rsv
respect
posit
predict
valu
neg
predict
valu
valu
interobserv
agreement
high
three
pathogen
tabl
multiplexnat
detect
addit
pathogen
figur
present
either
alon
case
coinfect
case
tabl
singl
infect
includ
adenoviru
human
bocaviru
coronavirus
human
metapneumoviru
parainfluenza
virus
rhinovirusenteroviru
median
age
patient
singl
infect
year
percentil
month
percentil
year
p
case
found
children
among
patient
singl
infect
individu
male
median
age
year
percentil
month
percentil
year
thu
strong
trend
seen
male
gender
reach
statist
signific
p
observ
sole
base
demograph
would
requir
dedic
studi
howev
report
other
children
male
gender
may
suscept
sever
respiratori
diseas
coinfect
rsv
influenza
found
togeth
pathogen
influenza
found
coinfect
tabl
median
age
patient
coinfect
year
percentil
month
percentil
year
p
coinfect
detect
pediatr
patient
singl
coinfect
median
age
patient
year
lower
coinfect
result
prospect
evalu
liat
winter
season
figur
indic
excel
sensit
specif
detect
influenza
virus
rsv
compar
routin
diagnost
multiplexnat
liat
show
sensit
three
pathogen
specif
reach
influenza
influenza
rsv
compar
multiplexnat
qnat
four
discord
result
encount
concern
rsv
three
case
influenza
one
case
among
sampl
tabl
influenza
case
sampl
neg
test
twice
neg
repeat
test
liat
possibl
due
lack
sampl
materi
rsv
case
liat
score
three
sampl
posit
test
neg
multiplexnat
two
sampl
one
sampl
discord
result
resolv
qnat
viral
load
copiesml
vtm
respect
suggest
limit
sensit
multiplexnat
possibl
due
multiplex
target
sequenc
detect
copiesml
vtm
qnat
one
liat
sampl
line
result
copiesml
vtm
rsv
detect
sensit
influenza
copiesml
vtm
influenza
copi
ml
vtm
similar
rang
therebi
permit
detect
acut
ill
patient
typic
much
higher
viral
previou
studi
liat
compar
commerci
result
studi
suggest
liat
superior
sensit
compar
poct
howev
sampl
mostli
obtain
adult
patient
complement
studi
major
symptomat
children
tabl
week
week
influenza
cocircul
among
predominatli
pediatr
popul
figur
wherea
mostli
influenza
domin
among
adult
januari
feburari
switzerland
influenza
report
diseas
epidemiolog
evalu
perform
sentinella
surveil
network
base
weekli
notif
physician
mandatori
report
influenza
subtyp
diagnost
laboratori
liat
gener
valid
result
sampl
laboratori
liat
easi
handl
includ
inexperienc
personnel
featur
like
barcod
read
direct
transfer
result
laboratori
inform
system
save
time
elimin
manual
procedur
time
less
minut
plu
assay
time
minut
result
tat
minut
reach
even
person
minim
train
thu
liat
permit
rapid
respons
includ
decis
regard
antivir
therapi
influenza
well
cohort
patient
part
infect
control
institut
set
includ
outpati
clinic
emerg
room
intens
care
unit
follow
limit
note
first
batch
test
patient
sampl
possibl
peak
season
influenza
rsv
sequenti
test
may
result
loss
tat
advantag
sampl
per
hour
per
hour
per
hour
howev
partli
compens
direct
parallel
test
one
liat
instrument
second
liat
lack
identif
influenza
subtyp
detect
influenza
subtyp
may
influenc
isol
procedur
hospit
set
addit
immunocompromis
patient
may
risk
dual
infect
rare
usual
one
pathogen
domin
case
subsequ
multiplexnat
qnat
provid
semiquantit
result
help
identifi
main
driver
infect
liat
easi
handl
test
system
may
attract
use
personnel
train
profession
laboratori
analyst
howev
practic
qualif
program
correspond
document
requalif
everi
year
need
perform
accord
laboratori
regul
fail
intern
extern
qualiti
assur
program
conclus
liat
reduc
tat
compar
convent
multiplexnat
qnat
studi
sensit
liat
seem
equival
slightli
increas
current
multiplexnat
compar
specif
qnat
specif
similar
multiplexnat
thu
liat
seem
use
rapid
test
manag
decis
regard
infect
control
therapi
could
follow
qnat
document
viral
replic
clearanc
need
andor
multiplexnat
detect
respiratori
pathogen
author
declar
conflict
interest
